Clinical Trials

1,040 enrolled

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT06662786 2026-05-08

OrigAMI-2

1,000 enrolled

Colorectal Neoplasms

NCT06750094 2026-05-08

OrigAMI-3

700 enrolled

Colorectal Neoplasms

NCT07228832 2026-05-05

HARMONi-GI3

600 enrolled

Colorectal Neoplasms

NCT03504397 2026-05-04

Spotlight

565 enrolled 63 charts 1 FDA

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT04241185 2026-05-01

MK-3475-992

520 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06901531 2026-04-29

LUCERNA

500 enrolled

Tumor-Agnostic

Adenocarcinoma, Neoplasms

NCT06625320 2026-04-27

RASolute 302

500 enrolled

Pancreatic Neoplasms

NCT07412613 2026-04-22

Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

GastrointestinalOther solid neoplasm

386 enrolled

Resectable Colon Cancer

NCT04083235 2026-04-20

NAPOLI 3

770 enrolled 13 charts 1 FDA

Metastatic Adenocarcinoma of the Pancreas

NCT05253651 2026-04-07

MOUNTAINEER-03

400 enrolled

Colorectal Neoplasms

NCT03221426 2026-03-09

KEYNOTE-585

1,007 enrolled 25 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT04882241 2026-03-06

KEYNOTE-585

120 enrolled 17 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT06951503 2026-03-04

AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

560 enrolled

Colorectal Adenocarcinoma

NCT03675737 2026-02-27

KEYNOTE-859

1,579 enrolled 31 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT03143153 2026-02-17

CheckMate 648

970 enrolled 15 charts 1 FDA

Various Advanced Cancer

NCT07328919 2026-01-09

Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

Phase 3 Not yet recruiting

138 enrolled

Phase 3 Not yet recruiting

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT06093425 2025-12-17

Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

820 enrolled

Stomach Neoplasms

NCT04949256 2025-12-15

MK-7902-014

864 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT03615326 2025-12-11

MK-3475-811

738 enrolled 22 charts 3 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT07238283 2025-12-09

Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer

662 enrolled

First-line Treatment of Metastatic Pancreatic Cancer

NCT03358472 2025-12-03

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Phase 3 Not yet recruiting

89 enrolled 14 charts

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07262567 2025-12-03

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer

320 enrolled

Pancreatic Neoplasms

NCT01358877 2025-11-28

APHINITY

4,804 enrolled 45 charts 1 FDA

Breast

Breast Neoplasms

NCT06699212 2025-10-15

ECLIPSE

412 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04008030 2025-10-03

CheckMate 8HW

839 enrolled 22 charts 1 FDA

Colorectal Neoplasms

NCT04919226 2025-09-10

COMPOSE

EndocrineGastrointestinalNET

259 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT04607421 2025-08-14

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

831 enrolled 2 FDA